Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ: ELDN · Real-Time Price · USD
2.190
+0.220 (11.17%)
At close: Feb 6, 2026, 4:00 PM EST
2.180
-0.010 (-0.46%)
After-hours: Feb 6, 2026, 7:06 PM EST
Eledon Pharmaceuticals Employees
Eledon Pharmaceuticals had 31 employees as of December 31, 2024. The number of employees increased by 11 or 55.00% compared to the previous year.
Employees
31
Change (1Y)
11
Growth (1Y)
55.00%
Revenue / Employee
n/a
Profits / Employee
-$2,666,742
Market Cap
173.78M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 31 | 11 | 55.00% | 31 | 0 |
| Dec 31, 2023 | 20 | 3 | 17.65% | 20 | 0 |
| Dec 31, 2022 | 17 | 5 | 41.67% | 17 | 0 |
| Dec 31, 2021 | 12 | 2 | 20.00% | 12 | 0 |
| Dec 31, 2020 | 10 | 2 | 25.00% | 10 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Innate Pharma | 174 |
| ProQR Therapeutics | 166 |
| Zentalis Pharmaceuticals | 166 |
| Compugen | 74 |
| Cartesian Therapeutics | 66 |
| Sol-Gel Technologies | 34 |
| Opus Genetics | 18 |
| Tiziana Life Sciences | 9 |
ELDN News
- 1 day ago - Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 14 days ago - Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium - GlobeNewsWire
- 4 weeks ago - Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook - GlobeNewsWire
- 2 months ago - Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference - GlobeNewsWire
- 2 months ago - Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine - GlobeNewsWire
- 2 months ago - Eledon Pharmaceuticals, Inc. (ELDN) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript - Seeking Alpha
- 3 months ago - Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire